دورية أكاديمية
One versus two doses of ivermectin-based mass drug administration for the control of scabies: A cluster randomised non-inferiority trial.
| العنوان: | One versus two doses of ivermectin-based mass drug administration for the control of scabies: A cluster randomised non-inferiority trial. |
|---|---|
| المؤلفون: | Susanna J Lake, Daniel Engelman, Julie Zinihite, Oliver Sokana, Dickson Boara, Titus Nasi, Christina Gorae, Millicent H Osti, Sophie Phelan, Matthew Parnaby, Anneke C Grobler, Tibor Schuster, Ross Andrews, Margot J Whitfeld, Michael Marks, Lucia Romani, Andrew C Steer, John M Kaldor |
| المصدر: | PLoS Neglected Tropical Diseases, Vol 17, Iss 3, p e0011207 (2023) |
| بيانات النشر: | Public Library of Science (PLoS), 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Arctic medicine. Tropical medicine LCC:Public aspects of medicine |
| مصطلحات موضوعية: | Arctic medicine. Tropical medicine, RC955-962, Public aspects of medicine, RA1-1270 |
| الوصف: | BackgroundMass drug administration (MDA) based on two doses of ivermectin, one week apart, substantially reduces prevalence of both scabies and impetigo. The Regimens of Ivermectin for Scabies Elimination (RISE) trial assessed whether one-dose ivermectin-based MDA would be as effective.MethodsRISE was a cluster-randomised trial in Solomon Islands. We assigned 20 villages in a 1:1 ratio to one- or two-dose ivermectin-based MDA. We planned to test whether the impact of one dose on scabies prevalence at 12 and 24 months was non-inferior to two, at a 5% non-inferiority margin.ResultsWe deferred endpoint assessment to 21 months due to COVID-19. We enrolled 5239 participants in 20 villages at baseline and 3369 at 21 months from an estimated population of 5500. At baseline scabies prevalence was similar in the two arms (one-dose 17·2%; two-dose 13·2%). At 21 months, there was no reduction in scabies prevalence (one-dose 18·7%; two-dose 13·4%), and the confidence interval around the difference included values substantially greater than 5%. There was however a reduction in prevalence among those who had been present at the baseline assessment (one-dose 15·9%; two-dose 10·8%). Additionally, we found a reduction in both scabies severity and impetigo prevalence in both arms, to a similar degree.ConclusionsThere was no indication of an overall decline in scabies prevalence in either arm. The reduction in scabies prevalence in those present at baseline suggests that the unexpectedly high influx of people into the trial villages, likely related to the COVID-19 pandemic, may have compromised the effectiveness of the MDA. Despite the lack of effect there are important lessons to be learnt from this trial about conducting MDA for scabies in high prevalence settings.Trial registrationRegistered with Australian New Zealand Clinical Trials Registry ACTRN12618001086257. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1935-2727 1935-2735 |
| Relation: | https://doaj.org/toc/1935-2727; https://doaj.org/toc/1935-2735 |
| DOI: | 10.1371/journal.pntd.0011207 |
| URL الوصول: | https://doaj.org/article/e4994b90b4b3465981e600d80d818947 |
| رقم الأكسشن: | edsdoj.4994b90b4b3465981e600d80d818947 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 19352727 19352735 |
|---|---|
| DOI: | 10.1371/journal.pntd.0011207 |